Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer

Abstract Background Stereotactic ablative body radiotherapy (SABR) is an emerging treatment for patients with primary renal cell carcinoma (RCC). However, its impact on renal function is unclear. This study aimed to evaluate incidence and clinical factors predictive of severe to end-stage chronic ki...

Descripción completa

Detalles Bibliográficos

Autores principales:	Muhammad Ali, Kendrick Koo, David Chang, Phil Chan, Sheng F. Oon, Daniel Moon, Declan G. Murphy, Renu Eapen, Jeremy Goad, Nathan Lawrentschuk, Arun A. Azad, Sarat Chander, Mark Shaw, Nicholas Hardcastle, Shankar Siva
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2024-02-01
Colección:	Radiation Oncology
Materias:	Stereotactic ablative radiotherapy SABR Renal cell carcinoma RCC Chronic kidney disease End-stage renal disease
Acceso en línea:	https://doi.org/10.1186/s13014-024-02413-w
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!